Abstract

Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients. There is also evidence from randomized trials that transplantation for relapsed patients improves survival compared with conventional salvage chemotherapy. Phase II trials of radiolabeled antibody therapy are providing promising results. There is still no definitive evidence that any treatment of advanced low-grade lymphoma prolongs survival, although the use of allogeneic bone marrow transplantation is under investigation. Treatment designed to eradicate Helicobacter pylori can cause regression in approximately 50% of patients with gastric lymphomas of mucosa- associated lymphoid tissue, although long-term follow-up information is lacking. The results of treatment for mantle cell lymphoma are poor and there is no consensus on management. Most trials of primary central nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the blood-brain barrier in addition to radiation.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalCurrent Opinion in Hematology
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Survival
Mantle-Cell Lymphoma
Drug Therapy
Marginal Zone B-Cell Lymphoma
Homologous Transplantation
Gastric Mucosa
Blood-Brain Barrier
Bone Marrow Transplantation
Helicobacter pylori
Lymphoma
Central Nervous System
Transplantation
Radiation
Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Non-Hodgkin's lymphoma. / Bierman, Philip Jay; Armitage, James Olen.

In: Current Opinion in Hematology, Vol. 3, No. 4, 01.01.1996, p. 266-272.

Research output: Contribution to journalReview article

@article{6f743e32ca1d495c8b3cf3c8b93d6662,
title = "Non-Hodgkin's lymphoma",
abstract = "Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients. There is also evidence from randomized trials that transplantation for relapsed patients improves survival compared with conventional salvage chemotherapy. Phase II trials of radiolabeled antibody therapy are providing promising results. There is still no definitive evidence that any treatment of advanced low-grade lymphoma prolongs survival, although the use of allogeneic bone marrow transplantation is under investigation. Treatment designed to eradicate Helicobacter pylori can cause regression in approximately 50{\%} of patients with gastric lymphomas of mucosa- associated lymphoid tissue, although long-term follow-up information is lacking. The results of treatment for mantle cell lymphoma are poor and there is no consensus on management. Most trials of primary central nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the blood-brain barrier in addition to radiation.",
author = "Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00062752-199603040-00004",
language = "English (US)",
volume = "3",
pages = "266--272",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Non-Hodgkin's lymphoma

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients. There is also evidence from randomized trials that transplantation for relapsed patients improves survival compared with conventional salvage chemotherapy. Phase II trials of radiolabeled antibody therapy are providing promising results. There is still no definitive evidence that any treatment of advanced low-grade lymphoma prolongs survival, although the use of allogeneic bone marrow transplantation is under investigation. Treatment designed to eradicate Helicobacter pylori can cause regression in approximately 50% of patients with gastric lymphomas of mucosa- associated lymphoid tissue, although long-term follow-up information is lacking. The results of treatment for mantle cell lymphoma are poor and there is no consensus on management. Most trials of primary central nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the blood-brain barrier in addition to radiation.

AB - Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients. There is also evidence from randomized trials that transplantation for relapsed patients improves survival compared with conventional salvage chemotherapy. Phase II trials of radiolabeled antibody therapy are providing promising results. There is still no definitive evidence that any treatment of advanced low-grade lymphoma prolongs survival, although the use of allogeneic bone marrow transplantation is under investigation. Treatment designed to eradicate Helicobacter pylori can cause regression in approximately 50% of patients with gastric lymphomas of mucosa- associated lymphoid tissue, although long-term follow-up information is lacking. The results of treatment for mantle cell lymphoma are poor and there is no consensus on management. Most trials of primary central nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the blood-brain barrier in addition to radiation.

UR - http://www.scopus.com/inward/record.url?scp=0030036920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030036920&partnerID=8YFLogxK

U2 - 10.1097/00062752-199603040-00004

DO - 10.1097/00062752-199603040-00004

M3 - Review article

C2 - 9372087

AN - SCOPUS:0030036920

VL - 3

SP - 266

EP - 272

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -